Fig. 2

ZEB1 deletion in stromal fibroblasts suppresses PyMT tumour formation, growth and metastasis. a The scheme of the transgenic mouse model for breast cancer. b Immunohistochemical staining of ZEB1 in PyMT-Fib-WT and -cKO tumours (images are representative of images from five mice). Insets display higher magnifications of boxed areas. c Immunofluorescence staining of ZEB1 and GFP in primary tumours of PyMT-Fib-WT-ROSA-YFP and PyMT-Fib-cKO-ROSA-YFP reporter mice (images are representative of images from five mice). Nuclei are counterstained with DAPI. d Kaplan–Meier analysis of mammary tumour progression in PyMT-Fib-WT (20 mice), -Het (20 mice) and -cKO (23 mice) females. Log-rank test. e The number of PyMT-Fib-WT and -cKO mice at 16 weeks of age (10 mice, each) that developed indicated numbers of palpable tumours. f Whole-mount Carmine red staining of neoplastic mammary glands from PyMT-Fib-WT and -cKO mice at 8, 10 and 13 weeks of age (images are representative of images from five mice). g Quantification of neoplastic areas in the mammary glands as shown in f (n = 5 independent experiments). Two-sided Student’s t test. h Haematoxylin and eosin (H&E) staining of lungs from PyMT-Fib-WT and -cKO mice at 9 weeks post detection of mammary tumours (six mice, each). Magnified areas of boxed sections are shown in right panels. i The number of lung colonies in the cohorts as shown in h. Two-sided Student’s t test. j RT-qPCR analyses of PyMT expression levels in circulating nucleated cells (CNCs) and primary tumour cells (PTCs) prepared from PyMT-Fib-WT and -cKO mice (n = 6 independent experiments). Two-sided Student’s t test. All data are represented as mean ± s.d. **P < 0.01, n.s. not significant. The source data are provided as a Source Data file